Major histocompatibility complex–peptide complex on dendritic cells and T-cell receptor (MHC–peptide complex; TCR)

Major histocompatibility complex–peptide complexes (MHC–peptide complexes) are formed when antigenic peptides are loaded onto MHC class I or II molecules in dendritic cells and other antigen-presenting cells. These complexes present peptides on the cell surface to T-cell receptors (TCRs), which are found on T lymphocytes. Recognition of the MHC–peptide combinations by TCRs is essential for adaptive immunity: cytotoxic CD8+ T cells recognize MHC class I–peptide complexes, while CD4+ helper T cells recognize MHC class II–peptide complexes. The extensive polymorphism and allelic diversity of MHC molecules allow for presentation of a wide variety of peptides, influencing susceptibility to infection, cancer, and autoimmunity. The physical interaction between the peptide-loaded MHC molecule on dendritic cells and the TCR on T cells triggers specific immune responses, including activation and clonal expansion of T cells, target cell killing, or tolerance induction. This process is highly regulated and subject to therapeutic modulation, making the MHC–peptide/TCR axis a fundamental therapeutic target in immunology, cancer therapy, and modulation of autoimmunity. Key notes for structuring information: - The query refers to an interaction ("MHC–peptide complexes on dendritic cells and T-cell receptors") not an individual protein: this is not usually the canonical form of a drug target but describes a critical immune molecular recognition event. - For structured data, separate MHC molecule (e.g. “Major histocompatibility complex class I heavy chain”) and TCR (“T-cell receptor alpha/beta chain”) as distinct canonical targets. - Drug interaction is mainly with immune modulation (checkpoint inhibitors, co-stimulation blockers) rather than direct blockade of the MHC–peptide:TCR interface. - Most entries, except the description and biological roles, should default to canonical names ("Major histocompatibility complex class I/II molecule"; "T-cell receptor") for structured database extraction. If you need individual canonical targets (e.g., MHC molecule or TCR) instead of the interaction complex, specify which to focus on for future queries.

Other names

MHC–peptide complexpMHCT-cell receptorTCRHLA–peptide complex (in humans)MHC–TCR interaction

Blockade of T-cell activation (by interfering with co-stimulation or MHC–TCR interaction); Immune checkpoint inhibition (enhancing TCR response against antigens presented via MHC); Downregulation/modulation of antigen presentation